Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

This study found that, among 100 patients with alopecia areata, the most prevalent subtype was patchy alopecia areata, with characteristic trichoscopic features including black dots, yellow dots, and empty hair follicles.

This case report describes a 43-year-old male patient with alopecia totalis successfully regaining all his hair after six months of treatment with tofacitinib, with no relapse observed after one year.

This study reports two siblings with severe combined immunodeficiency due to a mutation in the FOXN1 gene, characterized by T-cell immunodeficiency, alopecia totalis, and nail dystrophy.

This article discusses various types of alopecia, their causes, and potential treatments, but it provides no new clinical results or studies.

This case study reports that a 3 ½ year-old male with vitamin D-dependent type II rickets showed partial improvement in alopecia and rickets when treated with high doses of 1,25(OH)2 vitamin D3.

This case report highlights an unusual trichoscopic appearance in alopecia areata due to dithranol staining, which may obscure typical patterns and reveal atypical vascular features in the interfollicular spaces.

The document concludes that various hair disorders have different treatments, including medication, surgery, and addressing underlying causes.

This review discusses the evidence for biotin supplementation in treating hair loss, concluding that its benefits are poorly supported by data and advising against routine use without more compelling future trials.

The first Japanese family with Marie Unna hereditary hypotrichosis showed hair condition improvement in a child and highlighted the risk of misdiagnosis.

This study observed that while alopecia treatment in patients showed some improvements in quality of life and anxiety scores at six months, these changes were not statistically significant.

This review outlines treatment options for alopecia areata and highlights promising new therapies like targeted immune interventions and platelet-rich plasma application, but reports no new clinical results.

The document concludes that scalp conditions have various causes and can present in many different ways.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This study found that a combination treatment using oral and topical steroids with topical minoxidil was well-tolerated in children with severe recalcitrant alopecia areata, showing good responses except in alopecia universalis cases.

This article discusses various causes and prevention methods for male pattern baldness but reports no new research findings.

A man had an unusual type of hair loss that didn't match known patterns and didn't improve with treatment.

In this study, the HairCheck device was reported to accurately assess changes in hair density and diameter, suggesting its usefulness in monitoring alopecia progression and treatment response.

This collection of case reports discusses various rare dermatological conditions, including alopecia totalis with amyloidosis and multiple myeloma, and provides descriptive insights without reporting new clinical findings.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This study found that Chinese patients with alopecia totalis or universalis had an earlier onset, longer disease duration, and more severe quality of life impact compared to those with patchy alopecia areata.

This study found that among Chinese patients with alopecia areata, those with alopecia totalis/universalis had an earlier onset, longer duration, and more severe quality of life impact compared to those with patchy alopecia.

This study observed that Chinese patients with alopecia totalis or universalis had an earlier onset, longer duration, and more severe impact on quality of life compared to those with patchy alopecia areata.

This study enrolled nine patients to investigate the effects of oral psoralen and ultraviolet A therapy plus oral prednisolone for treating alopecia areata.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This review examines existing and potential treatments for alopecia areata but does not report new clinical results, emphasizing the need for future therapies that target immune pathways or protect hair follicles from inflammation.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

This article presents a discussion on alopecia areata in infants and concludes that the condition's occurrence in this age group is not as rare as previously thought; it offers no new data.